Chronic Inducible Urticaria: Part II by Borlu, Murat et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books






Chronic Inducible Urticaria: Part II
Murat Borlu, Salih Levent Cinar and Demet Kartal
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/intechopen.68754
Abstract
Physical urticaria (PU) is a subgroup of acquired, chronic inducible urticaria which is 
associated with a known physical trigger. In PU, the symptoms are induced by exog‐
enous physical triggers, such as friction, pressure, vibration, cold, heat, or solar radiation. 
All the PUs may manifest with both wheals and angioedema at the sites of the triggers 
with the exceptions that urticaria factitia (UF) (symptomatic dermatographism) presents 
with wheals only and pressure urticaria presents with angioedema only. More than one 
form of physically induced urticarias can be present in one patient.
Keywords: physical urticaria, dermatographism, cold urticaria, heat urticaria, solar 
urticaria
1. Introduction: physical urticarias
Physically induced urticarias are symptomatic dermatographism, cold contact urticaria, heat 
contact urticaria, solar urticaria, delayed pressure urticaria, and vibratory urticaria. More 
than one of these can be present in a single patient making it difficult to manage. A known 
and repeatable physical trigger is the causative agent in these entities.
2. Urticaria factitia (dermatographism)
Urticaria factitia (UF) is also known as dermographic urticaria and symptomatic dermatog‐
raphism. UF is the most common type of physical urticaria (PU) [1]. It must be differenti‐
ated from simple dermatographism in which whealing without itching is seen after moderate 
stroking of the skin [2]. White dermatographism which is seen in atopic patients is not related 
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to UF [3]. UF is commonly seen in young adults and the mean duration of the disease was 
reported 3–9 years in different studies. The etiology of UF is still unknown [4]. Infections 
(hepatitis, upper respiratory tract infections), medications (progesterone, statins), and diabe‐
tes mellitus have been accused, but still, there is less evidence [5]. The pathogenic mechanism 
is believed to be the release of histamine following a mechano‐immunological trigger [6].
In UF, itchy, white/pink/red wheals are observed after friction, scratching, rubbing, or tight 
clothing. Wheals appear in a few minutes following the trigger and may last a few hours. 
UF should come to mind in such cases, and the diagnosis should be made after positive skin 
provocation test [7].
The provocation in UF can be done by scratching or rubbing the skin with a blunt object (e.g., 
closed ballpoint pen tip or wooden tongue depressor). The flexor aspect of the forearm is the 
most suitable site for the provocation. Five to ten minutes of waiting time is mostly enough 
to conclude [8]. Recent guidelines suggest threshold testing with more advanced devices 
called the dermographometer. With this device, predefined and reproducible pressures can 
be applied to the testing area. The minimal force which is necessary to induce whealing can 
be determined with dermographometer and the disease activity in time (i.e., the patient’s 
response to therapy) can be easily monitored. A positive response is noted when the patient 
shows a wheal response and complain pruritus [9].
Treatment of UF is mostly symptomatic. Avoidance is the best strategy. It is possible to prevent 
or minimize whealing by some precautions. Decreasing mechanical irritation in daily life is 
the essential of the therapy [10]. For symptomatic cases, new generation, nonsedating antihis‐
tamines are suggested as first‐line treatment. In case of failure, the dose can be increased to 
fourfold. Type of the antihistamine can be changed, leukotriene antagonists and/or H2 anti‐
histamines can be added [11]. Next two drugs in the treatment course are cyclosporine A and 
omalizumab [10, 12].
3. Delayed pressure urticaria (DPU)
Delayed pressure urticaria (DPU) manifests with pink/red whealing or angioedema of the 
skin at sites of sustained pressure, such as tight clothing, walking, or sitting down. It is called 
delayed because hours (6–8 h) are necessary for it to manifest [9, 13]. The patients suffer from 
severe pain and burning sensation in contrast to other PUs. Fatigue and arthralgia can accom‐
pany. The quality of life is much more affected in DPU patients when compared with other 
forms of PU. Sometimes, the lesions can last up to 72 h [14].
The diversity of symptoms suggests that other mediators such as cytokines and interleukins 
play a role in addition to histamine in the pathogenesis of DPU. There is evidence that IL‐1, 
IL‐3, IL‐6, and tumor necrosis factor alpha (TNF‐α) play a role in the etiopathogenesis [12]. 
More recently, neuropeptides, such as substance P and calcitonin gene‐related peptide, have 
also shown to be taking a part in the formation of DPU [15].
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After taking proper history of the patient, if there is a suspicion of DPU, skin provocation 
test should be performed. Either weighted rods (7 kg weight with a 3 cm wide strap over 
the shoulder) or dermographometer can be used for this purpose. Weighted rods should be 
applied for 15 min and the dermographometer for 70 sec. If a red‐colored edema appears after 
6 h of the trigger, the test result is accepted as positive [16].
The etiology of DPU is not clear, so symptomatic treatment and avoidance are the mainstay of 
the therapy. Angioedema can be made less frequent or less severe with H1 antihistamines [3]. 
Most of the time, additional efforts are necessary to control the attacks. Leukotriene antago‐
nists, dapsone, sulfasalazine, or combinations of these have been reported to be successfully 
used in the literature. Systemic steroids can be used in flare‐ups. Recent studies show the 
benefit of omalizumab, but further controlled studies are necessary [17]. Anecdotal reports 
have shown the efficacy of intravenous immunoglobulins, tranexamic acid, and chloroquine 
[18, 19]. More recently, good results with gluten‐free diet have been reported [14]. Cassano 
et al. reported remission of DPU after eradication of Blastocystis hominis surprisingly [13].
4. Heat contact urticaria (HCU)
Heat contact urticaria (HCU) is a rare type of PU in which wheals appear after contact to 
objects with temperature higher than the skin temperature itself [20]. The lesions emerge 
within a few minutes after the trigger and last for a few hours. Most of the patients are 
20–45‐year‐old females. Most of the patients with HU have additional systemic symptoms 
such as weakness, headache, flushing, diarrhea, shortness of breath, and, even sometimes, 
syncope [21–23]. Some familial cases with autosomal dominant inheritance have been shown 
[2]. Most of the time, the trigger is a warm bath. Hot air, heating pads, open fire, heated stove, 
hair dryers, and indirect sunlight can also cause HU [24].
In case of a suspicion, container filled with hot water should be applied for about 5 min to the 
skin, or the patient should be asked to shower with hot water at a temperature of 45°C. If the 
testing area shows a palpable and clearly visible wheal and flare, it is accepted as a positive test. 
In most of the cases, a burning sensation can accompany the itching. In patients with a positive 
test result, stimulation time and temperature threshold levels should be measured [25].
Generalized HU must be differentiated from cholinergic urticaria. In HU, the whealing and 
flares are limited to the contact areas. The lesions are mostly in similar size and morphology. 
On the contrary, cholinergic urticaria is caused by an increase in the body core temperature 
and the lesions are small pinpoint hives with flushing [26].
In HCU, the principal of the treatment is to avoid heat if possible. Sometimes, heat desensiti‐
zation can be effective. For symptomatic cases, H1 antihistamines are the first‐line treatment, 
and in case of failure, the dose can be increased up to fourfold [26]. Omalizumab, montelu‐
kast, and cyclosporine are the third‐line treatments [27]. Systemic steroids, colchicine, and 
disodium cromoglycate can be used in resistant cases [8].
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5. Cold contact urticaria (CCU)
Cold contact urticaria (CCU) is characterized by the appearance of wheals and angioedema 
after exposure to cold. Lesions occur a few minutes following the cold contact. Lesions usually 
do not spread beyond the contact area [28]. This form of PU can be fatal in some cases. After 
extensive cold contact, severe angioedema or shock can be seen, mostly following swimming 
in cold water [29]. CCU is mostly seen in young adults and can continue for 5–8 years [2].
There are some rare variants of CCU. In some cases, CCU lesions develop 24–48 h after cold 
exposure. In this case, it is called delayed CCU. In cold‐ dependent dermatographism, the lesions 
are seen in cold‐exposed and mechanically stimulated areas. Cold‐ induced cholinergic urticaria 
is the case that happens after physical exercise in cold air [30]. Familial cold auto‐inflamma‐
tory syndrome (FCAS) is a rare autosomal dominant condition in which wheals appear within 
2 h of systemic cold exposure. The lesions in this syndrome cannot be brought out by localized 
cold exposure. In FCAS, CIAS1/NLRP3 mutation leads to the activation of NLRP3 inflamma‐
some complex, and finally, interleukin‐1β is released from the mast cells. That is why FCAS 
responds dramatically to interleukin‐1 antagonists [31].
CCU lesions and symptoms arise as a result of the release of some mediators such as hista‐
mine, prostaglandin D2, platelet‐activating factor, and leukotrienes. Yet, it is not known why 
cold exposure causes the release of these mediators [32]. Half of the CCU patients are positive 
for antibodies against immunoglobulin E (IgE). IgE binding of some possible, unproven cold‐
depended skin antigens can be the reason of mast cell degradation [33]. It is also shown that 
CCU patients have circulating histamine‐releasing factors and positive autologous serum skin 
test (ASST) [34].
Suspecting CCU or angioedema, one should perform cold stimulation test since fatality has 
been reported in several cases. In this test, the volar aspect of the forearm is exposed to ice cube 
in a thin plastic bag for 5 min. Ten minutes after the removal of the bag, the response should 
be assessed. If a well‐demarcated, palpable wheal with a pruritic and burning sensation is 
present, the test is considered as positive. Ice cube should be in a thin bag in order to avoid 
any confusion with aquagenic urticaria [35]. Further critical temperature threshold tests with 
sophisticated devices can enable the patients to avoid situations that cause whealing [28]. More 
accurate testing is possible with computer‐aided thermoelectric Peltier device. This device can 
also be used for the evaluation of the success of the treatments. In most of the studies, the criti‐
cal temperature threshold is about 15–20°C [36]. The avoidance of below threshold tempera‐
tures is hard to manage in daily life. Even so, the patients should be warned to avoid contact 
with subthreshold temperatures.
The essential of the treatment of CCU is to avoid cold exposure. Non‐sedating H1 antihista‐
mines are accepted as the first‐line therapy by the current European Academy of Allergy and 
Clinical Immunology (EAACI)/Global Allergy and Asthma European Network (GA2LEN)/
European Dermatology Forum (EDF)/World Allergy Organization (WAO) guidelines [5]. 
Usually high doses of H1 antihistamines are necessary to control CCU. Siebenhaar et al. 
claimed that high dose of desloratadine is better in controlling CCU when compared with 
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the standard dose [37]. Likewise, Magerl et al. reported that H1 antihistamine up‐dosing 
increases the success rate in the treatment of CCU [38].
In case of failure of therapy with H1 antihistamines, there is lack of well‐studied alternative 
treatment options. Boyce JA reported successful treatment of cold‐induced urticaria/anaphy‐
laxis with omalizumab (anti‐IgE) [39]. In 2011, Gualdi et al. claimed that a patient who had 
CCU healed with the use of etanercept for the treatment of co‐existing psoriasis vulgaris. 
It was the first case report regarding the efficacy of etanercept in CCU [40]. Interleukin‐1 
receptor antagonist (anakinra) was shown to be effective in controlling severe idiopathic cold 
urticaria [41]. But more controlled studies are necessary to show the effects of omalizumab, 
etanercept, and anakinra in CCU.
Cold tolerance induction and maintenance therapy can also be tried with precaution due to the 
risk of anaphylaxis. In this procedure, the patient starts daily showers, first with water temper‐
atures above the threshold and in time, the temperature of the water is decreased gradually. 
Acquired tolerance is maintained with daily cold showers for a long time [42].
6. Vibratory urticaria (VU)
Vibratory urticaria (VU) is a rare form of PU in which whealing and pruritus of the skin is 
observed after vibration at the contact area [43]. For proper diagnosis, provocation testing can 
be done by using a laboratory vortex mixer at a frequency of 1000 r.p.m. Test is considered 
positive with swelling 10 min after provocation [4]. Nonsedating H1 antihistamines are the 
first‐line therapy [9].
7. Solar urticaria (SU)
Solar urticaria (SU) is characterized by wheals and sometimes angioedema after visible or 
ultraviolet (UV) light exposure [44]. Young adults are more commonly affected with a female 
predominance. The lesions which develop within 10 min of solar exposure are limited to the 
exposed areas. There are some variants of SU. Monfrecola et al. reported a case of solar urti‐
caria with delayed onset [45]. Torinuki reported two cases with solar urticaria manifesting 
pruritic erythema but no whealing [46].
It is thought that some unknown photo‐allergens that are produced in the skin after sun expo‐
sure cross‐react with IgE on mast cells, and as a result, histamine and other inflammatory 
mediators are released. Norris et al. and Esdaile et al. claimed that bruised skin is more prone 
to the formation of SU. They tried to explain this by the migration of photo‐allergens into the 
skin through damaged vessels [47, 48].
In a chronic urticaria patient, after history taking, if there is a suspicion of SU, we should per‐
form provocation test. For this purpose, solar simulators can be used. Provocation should be 
performed on body areas which are usually not exposed to sunlight, such as the buttocks, and 
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UVA, UVB, and visible light should be used separately. In a positive test result which means 
flare and whealing within 10 min of the exposure, threshold testing should also be done using 
increasing radiation doses [8].
It is difficult to manage SU. Avoidance of the sunlight exposure is almost impossible. 
According to the guidelines, H1 antihistamines are the first‐line treatment options. But only 
one‐third of the patients respond well to the antihistamines. Repeated sunlight exposure can 
induce tolerance [45]. For this purpose, PUVA and narrow‐band UVB can be used. Güzelbey 
et al. reported successful treatment of SU with anti‐immunoglobulin E therapy [49]. There are 
few other studies in the literature showing the efficacy or inefficacy of omalizumab [50, 51].
Hughes et al. and Correia et al. reported that SU can be successfully treated with intravenous 
immunoglobulin [52, 53]. On the contrary, Llamas‐Velasco et al. claimed that intravenous 
immunoglobulin was ineffective in the treatment of SU [54]. In 2011, Haylett et al. revealed 
that systemic photoprotection was possible with alpha‐melanocyte‐stimulating hormone 
(afamelanotide). Its mechanism of action is to increase melanization of the skin. With this 
effect, it protects the skin from the penetration of UV and visible wavelengths [55].
8. Conclusion
Physically induced urticarias are hard to manage. Avoidance is the best treatment option, 
but it is impossible most of the time. We should be alert that more than one form can be 
together in a patient. Although antihistamines are the first‐line therapy, usually other options 
are required to manage.
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